After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...